Specimen - Zn 1:1, active only when bound
Zinc Thymulin: Why Thymulin Is Active Only When Bound to Zinc
The single bound metal that switches the peptide on - and why every reported thymulin effect is, underneath, a zinc story.
The short version, in plain words
Zinc thymulin is the working form of the peptide. Picture the nonapeptide - the nine-link chain - as a tiny lock, and a single zinc atom as the only key that fits. Slot the zinc in and the chain folds into its active shape and switches on. Take the zinc away, and the same chain goes limp and does nothing. That is not a side detail; it is the whole mechanism. It was proven by chelating - chemically pulling out - the zinc, which killed the activity, then adding zinc back, which restored it, at exactly one zinc per peptide. So whenever a study reports a thymulin effect, zinc is quietly in the room.
The 1:1 zinc bond, and how it was proven
Thymulin's defining fact is stoichiometric: one zinc(II) ion per peptide molecule. In the original 1982 work, treating the serum thymic factor with the metal chelator Chelex 100 abolished its biological activity in the rosette assay, and activity was restored by zinc salts - with a 1:1 metal-to-peptide molar ratio giving optimal activation, confirmed by atomic absorption spectrometry [1]. A few other metals could partially substitute, but zinc was the physiological activator, and the authors named the zinc-bound active form thymulin [1].
The structural consequence followed: the zinc-bound peptide adopts a specific three-dimensional conformation, detectable by NMR, that the zinc-free apopeptide does not [2]. So the zinc is not a passenger - it organizes the active shape. The apopeptide (sometimes called apothymulin) is biologically inactive until zinc is restored [2].
Why thymulin needs zinc to work
Binding one zinc ion per peptide drives a specific active conformation; the zinc-free apopeptide is inactive [2]. In the original work, chelating zinc abolished activity and adding zinc back restored it at a 1:1 metal-to-peptide ratio [1]. Zinc is the switch, not a cofactor in the loose sense - without it, the molecule is present but silent.
Zinc status, thymulin activity, and the interpretation problem
Because the active species is zinc-loaded, serum thymulin activity behaves as a readout of the body's zinc economy. In mild human zinc deficiency, thymulin activity fell despite normal plasma zinc and was corrected by zinc repletion [3]. In cervical-carcinoma patients, active thymulin was reduced despite normal plasma zinc - attributed to elevated alpha-2-macroglobulin competing for zinc - and the reduction tracked decreased natural-killer-cell activity and IL-2 production [13]. In aging thymus tissue, zinc-bound metallothionein isoforms may sequester zinc and lower its bioavailability for thymulin activation [14].
This is also the literature's central interpretation problem, and the atlas marks it as a scorched gap: because activity is strictly zinc-dependent, a reported thymulin effect can be hard to separate from a zinc effect. Studies that supply thymulin and zinc together are describing the active complex, but disentangling the peptide's own contribution from zinc status is genuinely difficult [2][14].
What zinc dependence does not tell you
Zinc dependence explains how thymulin switches on; it says nothing about a human dose, a human benefit, or safety. There is no established human thymulin dose, native thymulin's human pharmacokinetics are not well characterized, and thymulin is a research peptide rather than an FDA-approved drug or a dietary supplement. The zinc mechanism is the most solid thing in the file - and it is mechanism, not medicine. The thymulin dosage in studies page keeps that line clear.